ArticlePLoS neglected tropical diseases2026
Proceedings of the inaugural symposium on dengue human challenge studies "Challenging the norm: Accelerating dengue countermeasures through human studies".
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On 12th June 2025, Duke-NUS Medical School, supported by the Global Dengue and Aedes-Transmitted Diseases Consortium (GDAC), hosted a one-day symposium in Singapore titled "Challenging the norm: Accelerating dengue countermeasures through human challenge studies". Comprising sessions on both dengue and other viral infection models, the symposium explored how human challenge studies could address gaps in dengue pathogenesis and immunity to inform vaccine development and application. Keynote speakers highlighted persistent challenges in dengue vaccine development, including incomplete protection across all four dengue viruses, complexities in dengue immunity, and past safety concerns that have influenced regulatory pathways. Case studies from Thailand and Bangladesh illustrated the feasibility and safety of dengue challenge studies in endemic settings. Parallel discussions drew lessons from human infection models of SARS-CoV-2 and other respiratory viruses that are directly relevant to expanding the use of dengue human challenge studies. Sessions on public engagement and regulatory frameworks emphasised the importance of trust, transparent communication, and harmonisation in the design, conduct, and acceptance of challenge studies. Overall, the symposium highlighted that human challenge studies, if implemented thoughtfully, can advance dengue vaccine research, accelerate clinical evaluation and regulatory approval of vaccine candidates, and support evidence-based public health strategies to strengthen global dengue control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.